TY - JOUR AU - Coiffier, Bertrand AU - Pro, Barbara AU - Prince, H Miles AU - Foss, Francine AU - Sokol, Lubomir AU - Greenwood, Matthew AU - Caballero, Dolores AU - Morschhauser, Franck AU - Wilhelm, Martin AU - Pinter-Brown, Lauren AU - Padmanabhan Iyer, Swaminathan AU - Shustov, Andrei AU - Nielsen, Tina AU - Nichols, Jean AU - Wolfson, Julie AU - Balser, Barbara AU - Horwitz, Steven PY - 2014 DA - 2014/01/23 TI - Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses JO - Journal of Hematology & Oncology SP - 11 VL - 7 IS - 1 AB - Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received ≥ 1 prior systemic therapy and patients with peripheral T-cell lymphoma (PTCL) who have received ≥ 1 prior therapy. Approval for PTCL was based on results (n = 130; median follow-up, 13.4 months) from the pivotal study of romidepsin for the treatment of relapsed/refractory PTCL. The objective is to present updated data (median follow-up, 22.3 months) and to characterize patients who achieved long-term responses (≥ 12 months) to romidepsin. SN - 1756-8722 UR - https://doi.org/10.1186/1756-8722-7-11 DO - 10.1186/1756-8722-7-11 ID - Coiffier2014 ER -